ArticleMolecular therapy : the journal of the American Society of Gene Therapy2017
Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor.Cellular oncology (Dordrecht, Netherlands) · 2022Pooled it
- Artesunate Nanoplatform Targets the Serine-MAPK Axis in Cancer-Associated Fibroblasts to Reverse Photothermal Resistance in Triple-Negative Breast Cancer.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Astrocyte-targeted siRNA delivery by adenosine-functionalized LNP in mouse TBI model.Molecular therapy. Nucleic acids · 2023Article
- Lipoproteins act as vehicles for lipid antigen delivery and activation of invariant natural killer T cells.JCI insight · 2023Article
- Changes in CoQInternational journal of molecular sciences · 2022Article
- Link between Omega 3 Fatty Acids Carried by Lipoproteins and Breast Cancer Severity.Nutrients · 2022Article
- Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition.Bioengineered · 2021Article
- Targeting Systems to the Brain Obtained by Merging Prodrugs, Nanoparticles, and Nasal Administration.Pharmaceutics · 2021Review
- Immunomodulatory Nanomedicine for the Treatment of Atherosclerosis.Journal of clinical medicine · 2021Review
- Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A.Communications biology · 2021Article
- New Nanoparticle Formulation for Cyclosporin A: In Vitro Assessment.Pharmaceutics · 2021Article
- Lipoproteins as Markers for Monitoring Cancer Progression.Journal of lipids · 2021Review
- Paving the way for small-molecule drug discovery.American journal of translational research · 2021Review
- Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy.Frontiers in oncology · 2021Review
- Nanoparticle-Based Approaches towards the Treatment of Atherosclerosis.Pharmaceutics · 2020Review
- Development and Characterization of Solid Lipid Nanoparticles Loaded with a Highly Active Doxorubicin Derivative.Nanomaterials (Basel, Switzerland) · 2018Article
- Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.International journal of nanomedicine · 2018Review
- Nanoparticle Technology: Having Impact, but Needing Further Optimization.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective delivery of anticancer drugs to rapidly growing cancer cells can be achieved by taking advantage of their high receptor-mediated uptake of low-density lipoproteins (LDLs). Indeed, we have recently discovered that nanoparticles made of the squalene derivative of the anticancer agent gemcitabine (SQGem) strongly interacted with the LDLs in the human blood. In the present study, we showed both in vitro and in vivo that such interaction led to the preferential accumulation of SQGem in cancer cells (MDA-MB-231) with high LDL receptor expression. As a result, an improved pharmacological activity has been observed in MDA-MB-231 tumor-bearing mice, an experimental model with a low sensitivity to gemcitabine. Accordingly, we proved that the use of squalene moieties not only induced the gemcitabine insertion into lipoproteins, but that it could also be exploited to indirectly target cancer cells in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.